Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the follicle stimulating hormone market?

The market for follicle stimulating hormone has seen robust growth over the last few years. The predictions suggest an increase from $2.03 billion in 2024 to $2.14 billion in 2025, with a compound annual growth rate (CAGR) of 5.4%. The substantial growth in recent history is due to factors such as a rise in hormonal disorders, an increase in demand for fertility treatments, expansion of FSH indications, introduction of new FSH products, and a growing need for safe and efficacious contraceptive alternatives.

What will be the follicle stimulating hormone market size in the future?

Prospects are promising for a robust expansion of the follicle stimulating hormone market in the upcoming years, with projections indicating a swell to $2.64 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.4%. The escalation throughout the predicted period is deemed to be engendered by factors such as broader therapeutic applications, escalating demand for combination therapies, the increasing requirement for reliable contraceptive alternatives, mounting healthcare needs associated with an aging populace, and market proliferation in significant zones. The period of forecast is also expected to witness major trends such as the emergence of sophisticated biosimilar FSH products, endorsements from regulatory institutions combined with market accessibility, technological progression in FSH manufacturing and distribution, and the rising need for effective contraceptive alternatives.

Get your follicle stimulating hormone market report here!

https://www.thebusinessresearchcompany.com/report/follicle-stimulating-hormone-global-market-report

What main drivers are fueling expansion in the follicle stimulating hormone market?

The follicle-stimulating hormone market is set to expand, given a rise in infertility cases. Infertility impacts both men and women’s reproductive systems, characterized by an inability to conceive despite frequent unprotected sexual interactions for a year or more. The follicle-stimulating hormone supports egg development in the ovaries and regulates a woman’s menstrual cycle. It also aids in the growth of testes in men and produces essential proteins for male fertility by encouraging the creation of healthy sperm. For example, the World Health Organization reported in April 2023 that approximately one in six adults globally, or nearly 17.5% of the adult population, were affected by infertility. Likewise, the Australian Bureau of Statistics revealed in October 2023 that there were 300,684 registered births in 2022, marking a 3% decrease from 2021. The fertility rate among Australian women stood at 1.63 births per woman. Thus, the growing rate of infertility boosts the follicle-stimulating hormone market’s growth.

What key areas define the segmentation of the global follicle stimulating hormone market?

The follicle stimulating hormone market covered in this report is segmented –

1) By Type: Recombinant FSH, Urinary FSH

2) By Application: Infertility Treatment, Assisted Reproductive Technology (ART), Other Applications

3) By End-Users: Infertility Center, Hospitals, Other End-Users

Subsegments:

1) By Recombinant FSH: Pure Recombinant FSH, Mixed Recombinant FSH Formulations

2) By Urinary FSH: Purified Urinary FSH, Urinary FSH Combined With Other Hormones

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12486&type=smp

Who are the dominant players expanding their reach in the follicle stimulating hormone market?

Major companies operating in the follicle stimulating hormone market include Pfizer Inc., Novartis AG, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Cipla Ltd., Ferring Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Livzon Pharmaceutical Group Inc., Emcure Pharmaceuticals Ltd., LG Chem’s life sciences, IBSA Group, Bharat Serums and Vaccines Limited, Anhui Anke Biotechnology Group Co. Ltd., Taj Pharmaceuticals Ltd., Genpharm Inc., Cadwell Laboratories Inc., Creative BioMart, Lee Biosolutions Inc., Trumac Healthcare, Midas Pharma GmbH, Biogenix Inc. Pvt. Ltd., Shanghai Techwell Biopharmaceutical Co. Ltd.

How are evolving market trends shaping follicle stimulating hormone Strategies?

Advancements in product development remain a crucial trend observed in the follicle-stimulating hormone market. The principal corporations operating in this market are concentrating on the creation of unique products to solidify their marketplace standing. As an illustration, Proov, a women’s health enterprise based in the US, unveiled the Proov Empower Perimenopause Testing System in July 2024. Designed to offer comprehensive and tailored insights into the impact of hormonal changes on women’s health and wellbeing, this non-invasive urinary test provides analysis at multiple time points, evaluating four influential hormones—FSH, estrogen marker E1G, progesterone marker PdG, and LH—and their relationship with perimenopausal symptoms. Furthermore, it offers the advantage of recurrent retesting, aiding women in monitoring hormonal fluctuations and associated symptoms, proving to be an invaluable tool during the transition to menopause.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12486

Which regions are emerging as leaders in the follicle stimulating hormone market?

North America was the largest region in the follicle stimulating hormone market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the follicle stimulating hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Ovarian Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-global-market-report

Parathyroid Hormone Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Hormone Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: